

ASX and Media Release

Viralytics attending JP Morgan Healthcare Conference, and release of new investor presentation

8 January 2018, Sydney, Australia: Viralytics Limited (ASX: VLA, OTC: VRACY) an innovator in the field of oncolytic immunotherapy, is attending the 36th Annual JP Morgan Healthcare Conference in San Francisco held 8-11 January. With over 8,000 attendees, this invitation-only event is the leading annual investment and business development focussed conference in the healthcare space. It will be attended by the major investment and pharmaceutical groups in the sector.

Viralytics is also pleased to advise that a new investor presentation is available on the home page of the company website: www.viralytics.com

The new presentation provides an overview of Viralytics, and includes:

- Viralytics' commercial focus
- Previously announced clinical highlights
- The three main clinical goals for the business in 2018

About Viralytics Ltd

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK®, is currently being studied in clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Cocksackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.

Enquiries:

Dr. Malcolm McColl
Chief Executive Officer
+61 2 9988 4000

Mr. Robert Vickery
Chief Financial Officer
+61 2 9988 4000